The measured dispersion was both energy-and gantry-dependent and ranged from 0 to 0.73 m. 
Introduction
One of the advantages of proton therapy over photon therapy is spatial conformity. The finite range of the proton beam allows delivery of treatment essentially without an exit dose, resulting in reduced total energy deposited in the patient. However, the quality of proton therapy treatments relies on accurately understanding range uncertainty to properly evaluate the treated volume; underestimating range uncertainty may result in missing the tumor target due to the potential shift of the sharp distal dose fall-off, and overestimating range uncertainty may result in unnecessary irradiation of normal tissues.
Primary sources of proton range uncertainty are the certainty of material stopping power and conversion of CT Hounsfield units (HU) to stopping power. Based on the Bethe-Bloch equation, the main parameters that drive the stopping power uncertainty are physical density and mean excitation energy 1 ; density variation in the material and uncertainties from mean excitation energy for various heterogeneous media further add to the stopping power uncertainty.
Additionally, uncertainties associated with assigning HU to relative stopping power increases the range uncertainty; measurement of HU numbers has uncertainty due to imaging parameters such as CT calibration and spatial resolution, and the conversion from HU to stopping power has uncertainty due to photon interaction cross-sections in the material that are not proportional to proton stopping power. A summary of these range uncertainties can be found elsewhere 1 . To account for the range uncertainties during treatment planning, the standard practice at our clinic is to study the treatment plan robustness to an uncertainty in the prescribed range of 3%.
Another source of range uncertainty is the proton beam momentum uncertainty. The theoretical range of a proton beam can be calculated by 2 ,
where R is the range, E i and E f are the initial and final beam kinetic energy, and S(E)/ρ is the mass-stopping power as a function of energy. For 100 -200 MeV proton beams, this equation reduces to
where E is in MeV. Fractional change in range due to change in beam momentum is
where γ is the relativistic gamma. A plot of range shift as a function beam energy and momentum offset are shown in Figure 1 . For 70 to 230 MeV beams, ( +1) = 1.93 to 1.80, respectively. Therefore, as a rule of thumb:
For the highest beam energy clinically used at our institution, 230 MeV, a 0.3% momentum deviation leads to a change in range of approximately 1% or 3 mm. It has been suggested that small momentum acceptance in a proton therapy accelerator will prohibit beams from reaching the patient when there is a considerable energy deviation 3, 4 . In this technical note, we report measurements of the upper bound on momentum deviation that can reach a patient during treatment. 
Background
Beam steering in an accelerator is performed by applying Lorentz forces, and the effects of the magnetic fields depend on particle momentum. If the particle momentum is slightly offset from a reference momentum or if the particle beams are not monochromatic, then the deflection of a particle with the wrong energy will deviate from the trajectories of a particle with a nominal momentum. The variation in the deflection in a bending magnet caused by a momentum error is called the dispersion, and consequently, the dispersion is present only in the bending plane of the dipole magnets, which is specified as the -axis in this report. The magnitude of the positional deviation is characterized by
where ∆ is the shift from the reference trajectory, = ( − 0 )/ 0 is the fractional momentum offset of the beam, 0 is the nominal beam momentum set by the magnets, and ( ) is the dispersion function at location s.
Typically, beam range is measured periodically as a part of beam energy quality assurance 6 , but the spot position is always measured by the SPM during treatment. If dispersion is not zero at the spot position monitor, the delivered spot position with respect to a nominal position can be used to set an upper bound on momentum deviation. Range variation due to the momentum offset can then be calculated using Equation (3). Experimentally, the dispersion can be measured by changing the beam momentum or by changing the magnetic field strengths. Magnetic rigidity, Bρ = 0 / , defines the required magnetic field strength for a given bending radius and particle momentum, where B is the magnetic field, ρ is the bending radius, 0 is the reference momentum, is the speed of light, and is the charge of particles. By changing the magnetic field strengths B, we can in effect adjust the nominal momentum 0 for a given bending radius ρ.
When a shift in beam position ∆ is measured as a function of or 0 , dispersion can be calculated using Equation (4) at the given location.
Materials and Methods
The proton center at our institution uses the Hitachi PROBEAT V synchrotron that delivers beams from 70 to 230 MeV for five treatment rooms, four of which have gantries: Gantries 1 -4.
All gantries utilize pencil beam scanning delivery with an identical gantry design. Protons are extracted from the synchrotron and transported through series of quadrupole magnets and dipole magnets to the treatment isocenter. A simplified schematic of our beam transport line is shown in Figure 2 . In the transport line, to first order, the source of dispersion is entirely from the series of 
Results
Beam position shift ∆ at the SPM in the bending plane ( -axis) as a function of measured for three different beam energies is shown in Figure 3 (a). The error bars indicate the standard deviation of the 300 spots for the reference momentum setting and that of momentum offset summed in quadrature. Dispersions measured by linear fit to the data are summarized in Table 1 .
Changes in range corresponding to 1 mm positional shifts at the SPM are also listed in Table 1 .
For the nominal momentum, = 0, spot position deviation for each of the 300 spots is shown in For 70 MeV and 140 MeV, beam was clipped for = 0.3%, and the decreased dose rate is seen in Figure 4 (a, b) . For 230 MeV, no obvious change in dose rate was observed for all momentum settings. Table 2 . For Gantry 1, dispersion was approximately zero at the SPM. However, as shown in Figure 6 , measured dose rate starts to decrease for δ ± 0.5% and decreases significantly for = ±0.6%, indicating that the beam was being clipped in the transport line. For ± 0.7%, the beam failed to reach the treatment room, even with the beam delivery interlocks turned off. This occurred due to non-zero dispersion in the beam line upstream of the SPM. Due to the nature of dipole optics, the location of maximum dispersion would occur between GB1 and GB2 dipole magnets for all four gantry rooms 5 Figure 6 : Measured dose rate in Gantry 1 for = %, ± . %, ± . %.
Discussion
In this study, we measured dispersion at the SPM for our highest beam energy in all four gantries, and we measured the dispersions of three beam energies in Ideally, spot position deviation would be measured at a location with a large dispersion function to achieve high sensitivity to deviations in momentum. Since gantries are generally designed to have zero or very small dispersion at the treatment isocenter, measuring spot position closer to the treatment isocenter would likely decrease the sensitivity of this dispersion test. Continuous monitoring of beam position at the largest dispersion location in the accelerator complex using a passive beam position monitor would be ideal. However, in a capacitive coupling device, low beam currents in our transport line --on the order of a few hundred nano-amps --would generate only a small signal that would likely be lost in the noise 9 . Another possibility to decrease the variation in particle range potentially reaching the patient is to reduce the diameter of the beam pipe at the position of largest dispersion. This option seems attractive because then one could eliminate the SPM to reduce multiple scattering in the nozzle and therefore decrease the spot size to the patient. However, one would likely still wish to retain the SPM to measure the spot size and to have a confirmation of the spot scanning magnetic fields.
Finally, it is worth noting that there are accelerators with a large momentum acceptance, such as fixed-field alternating gradient accelerators, which would be less sensitive to momentum deviation by design 10, 11 . For these accelerators, assuring the beam energy reaching the patient would still be necessary to ensure patient safety.
Conclusions
We measured beam dispersion in our clinical proton therapy system 0.5 m upstream of treatment isocenter. The dispersion was both beam energy-and gantry-dependent. Measured dispersion ranged from 0 -0.73 m across the four gantries for 230 MeV beams.
